Does Robert J. Hombach claim full beneficial ownership of the Seaport Therapeutics (SPTX) shares?

He disclaims full beneficial ownership of the reported Seaport Therapeutics shares. The filing states he only acknowledges beneficial ownership to the extent of his pecuniary interest in the trust-held shares, if any.

Seaport Therapeutics (SPTX) director’s trust purchases 13K shares in open market

Filing Impact

(Moderate)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Seaport Therapeutics director–related trust bought additional stock. On behalf of the Robert Joseph Hombach Revocable Trust, an open-market purchase of 13,000 shares of Seaport Therapeutics common stock was made at a weighted average price of $18.136 per share, with individual trades ranging from $17.65 to $18.27.

After this transaction, the trust holds 13,000 shares indirectly attributed to director Robert J. Hombach. He disclaims beneficial ownership of these shares for Section 16 purposes except to the extent of any pecuniary interest.

Insider Trade Summary

Net Buyer: 13,000 shares ($235,768)

Net Buy 1 txn

Insider HOMBACH ROBERT J.

Role null

Bought 13,000 shs ($236K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	13,000	$18.136	$236K

Holdings After Transaction: Common Stock — 13,000 shares (Indirect, By Robert Joseph Hombach Revocable Trust)

Footnotes (1)

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.65 to $18.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Key Figures

Shares purchased: 13,000 shares Weighted average price: $18.136 per share Price range: $17.65–$18.27 per share +1 more

4 metrics

Shares purchased 13,000 shares Open-market purchase on 2026-06-22

Weighted average price $18.136 per share Common stock purchase

Price range $17.65–$18.27 per share Multiple trades within the transaction

Shares held after transaction 13,000 shares Indirectly via Robert Joseph Hombach Revocable Trust

Key Terms

open-market purchase, weighted average price, Revocable Trust, pecuniary interest

4 terms

open-market purchase financial

"an open-market purchase of 13,000 shares of Seaport Therapeutics common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"bought at a weighted average price of $18.136 per share"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Revocable Trust financial

"for the Robert Joseph Hombach Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/24/2026 - 06:05 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMBACH ROBERT J.

(Last)

(First)

(Middle)

SEAPORT THERAPEUTICS, INC.

101 SEAPORT BLVD., FLOOR 12

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seaport Therapeutics, Inc. [ SPTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/22/2026		P		13,000	A	$18.136⁽¹⁾	13,000	I	By Robert Joseph Hombach Revocable Trust⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.65 to $18.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

2. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

	/s/ Lana Gladstein, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Seaport Therapeutics (SPTX) report for Robert J. Hombach?

Seaport Therapeutics reported an indirect open-market purchase of 13,000 shares. The shares were bought for the Robert Joseph Hombach Revocable Trust, reflecting a director-associated trust increasing its position in the company’s common stock.

At what price did the Seaport Therapeutics (SPTX) insider shares trade?

The 13,000 Seaport Therapeutics shares were bought at a weighted average of $18.136. According to the filing, individual trade prices ranged between $17.65 and $18.27 per share during the open-market purchase.

How many Seaport Therapeutics (SPTX) shares does the Hombach trust hold after this filing?

Following the reported transaction, the trust holds 13,000 Seaport Therapeutics shares. All of these shares are reported as indirectly owned through the Robert Joseph Hombach Revocable Trust associated with director Robert J. Hombach.

Is the Seaport Therapeutics (SPTX) transaction a direct or indirect holding for Robert J. Hombach?

The reported Seaport Therapeutics holding is indirect for Robert J. Hombach. The shares are owned by the Robert Joseph Hombach Revocable Trust, and he reports them as indirectly owned through that trust structure.